March 31, 2011 -- The Genetics Policy Institute (GPI) and Future Medicine have announced that its 2011/12 World Stem Cell Report will be published as a special supplement to the award- winning, peer-reviewed journal Regenerative Medicine. It was also announced that Regenerative Medicine becomes the platinum media sponsor of the GPI’s 2011 World Stem Cell Summit that will take place in Pasadena, California, October 3-5.
Bernard Siegel, Executive Director of GPI said, “We are proud to partner with the truly superb editorial team at Regenerative Medicine to elevate the World Stem Cell Report to PubMed status. This collaboration will allow the Report to reach an even broader global audience. We will continue to provide an array of specialized articles offering unique insights of leading policy-makers, regulators and experts in law, ethics, advocacy, industry and philanthropy from countries, regions and states. The Report provides a critical unmet need by providing a global framework to understand how the intersection of ethics, law, economics and society impact the advancement of regenerative medicine and the quest for cures.”
Elisa Manzotti, Editorial Director at Future Medicine said “We are delighted to be working with Bernie Siegel and GPI on this exciting collaboration. Our editorial team will take great care to ensure that the World Stem Cell Report articles deliver concise, timely and actionable intelligence to our readers. In becoming a platinum media sponsor of the World Stem Cell Summit, we recognize the Summit’s important role in bringing together leaders from around the globe to chart the future of regenerative medicine.”
The Report will be made available to all attendees at the World Stem Cell Summit. The Summit is the world’s largest interdisciplinary stem cell meeting and is organized this year by GPI, City of Hope, Cedars-Sinai Regenerative Medicine Institute, California Institute of Technology and the California Institute for Regenerative Medicine (CIRM). The Summit program will feature 170 prominent scientists, business leaders, regulators, policy-makers, advocates, economic development officers and experts in law and ethics, who will discuss the latest scientific discoveries, business models, legal and regulatory solutions and best practices. The Summit is expected to attract more than 2,000 attendees from 25 nations, 60 exhibitors and more than 150 endorsing organizations and media partners.
Copies of the report will be made available when the Summit launches in October and will be viewable on the Regenerative Medicine website www.futuremedicine.com/loi/rme.
For further information please contact:
Craig Canham, Corporate Public Relations, Future Science Group
T: +44 (0) 20 8371 6088
F: +44 (0) 20 8343 2313
E: c.canham@futuremedicine.com
ABOUT REGENERATIVE MEDICINE
Impact factor: 2.929
Indexed on MEDLINE & EMBASE
ISSN: 1746-0751
Volume: Number 6 (2011)
Frequency: 6 issues per year
Senior Editor
Chris Mason, Professor of Regenerative Medicine Bioprocessing, University College London, UK
Description
Apart from answering some of the most fundamental questions of biology and stem cell research, regenerative medicine offers unprecedented opportunities for developing new medical therapies for debilitating and life-threatening diseases.
Regenerative Medicine is the award winning forum for a fast-growing community of specialists to address the important challenges and advances that are now occurring in stem cell research and regenerative medicine. It delivers this essential information in concise, clear and attractive article formats.
The journal is a one-stop shop for all stakeholders in the field, with our unique News and Views section dedicated to providing concise updates on all important issues facing the regenerative medicine sector. By bringing together researchers, clinicians and policy-makers, from academia and industry, the journal is successfully helping to facilitate the translation of basic stem cell service into therapies for routine clinical practice.
The journal covers:
• Bench-to bedside translation and scale-up of stem cell and regenerative medicine therapies
• Potential application for stem cell-based strategies in pathological conditions
• Stem cell pluriopotency and emerging technologies
• Tissue engineering and characterization of engineered tissues
• Medical devices and artificial organ development
• Regulatory and reimbursement issues
• Ethical and legal perspectives
Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus
ABOUT FUTURE SCIENCE GROUP
The Future Science Group (www.future-science-group.com) is an expanding group of independent publishing companies active in the field of scientific information and endeavor, including Expert Reviews Ltd (formerly known as Future Drugs Ltd) Future Medicine Ltd and Future Science Ltd. As a leading provider of products and services for the medical, science and business communities, we present the most important scientific breakthroughs in an accessible and evaluated format, while at the same time providing the scientific community with uniq ue vehicles for disseminating forward-thinking research information and data. Complete listings of titles under each imprint are available at www.expert-reviews.com,
www.futuremedicine.com and www.future-science.com.
ABOUT GENETICS POLICY INSTITUTE (GPI)
GPI is a 501c3 nonprofit foundation with the mission to promote and defend stem cell research and its application in medicine to develop therapeutics and cures for many otherwise intractable diseases and disorders. GPI pursues this mission through production of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, special projects, speaking engagements, teaching initiatives and strategic collaborations.
